Cellectar Reports 2017 Financial Results and Provides a Corporate Update Conference call to be held tomorrow at 8:30 a.m. Eastern time

Cellectar Reports 2017 Financial Results

and Provides a Corporate Update

Conference call to be held tomorrow at

8:30 a.m. Eastern time

MADISON, Wis., March 21, 2018 - Cellectar Biosciences,

Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of

targeted treatments for cancer, today reported financial results for 2017 and provided a corporate update.

Fourth Quarter 2017 and Recent Corporate Highlights

"We made significant progress throughout 2017 advancing

our pipeline and PDC therapeutic platform both through our own clinical development programs and through strategic collaborations.

Our Phase 2 study for R/R MM and other B-Cell malignancies continues to move forward and we continue to be pleased with the results

of our ongoing Phase 1 clinical trial of CLR 131 as a treatment for advanced MM," said James Caruso, president and CEO of

Cellectar Biosciences. "We expect to achieve a number of important milestones in the coming months that should position us

well for continued progress throughout the balance of 2018 and beyond."

2017 Financial Results

Research and development expenses for 2017 were approximately

$9.5 million, compared with approximately $4.8 million for 2016. The increase is primarily attributable to increased support for

the ongoing Phase 2 clinical trial in hematologic malignancies, as well as expanded preclinical development costs. In addition,

2017 research and development expenses include one-time non-cash depreciation expenses of approximately $1.2 million associated

with shutting down the company's small-scale manufacturing operation.

General and administrative expenses were approximately $4.1

million for 2017, compared with approximately $4.7 million for 2016.

The net loss attributable to common stockholders for 2017 was

approximately $15.0 million, or $1.07 per share based on 14.0 million shares outstanding, compared with a net loss attributable

to common stockholders for 2016 of approximately $9.4 million, or $2.14 per share based on 4.4 million shares outstanding. The

results include non-cash, stock-based compensation expense of approximately $0.8 million in 2017 and $0.5 million in 2016.

Balance Sheet Highlights

Cash and cash equivalents as of December 31, 2017 were approximately

$10.0 million, compared with approximately $11.4 million as of December 31, 2016. During the fourth quarter of 2017 Cellectar raised

net proceeds of approximately $7.1 million in a registered direct offering of common stock and Series B preferred stock, as well

as a private placement of Series D warrants.

Management believes that

current cash and cash equivalents are sufficient to fund budgeted operations into the first quarter of 2019.

Cellectar will host a conference tomorrow beginning at 8:30

a.m. Eastern Time to review the financial results, provide a company update and answer questions.

Shareholders and other interested parties may participate by

dialing 844-751-1093 (U.S.) or 574-990-2954 (international) and providing conference ID 6674595. The call will also be broadcast

live on the Internet via the Company's website at http://investor.cellectar.com/events.cfm.

For those unable to participate in the live conference call

or webcast, a replay will be available beginning March 22, 2018 two hours after the close of the conference call. To access the

replay, dial 855-859-2056 or 404-537-3406. The replay passcode is 6674595.

The webcast will be archived on the Company's website

Cellectar's product candidates are built upon a patented delivery

and retention platform that utilizes optimized PDCs to target cancer cells. The PDC platform selectively delivers diverse oncologic

payloads to cancerous cells and cancer stem cells, including hematologic cancers and solid tumors. This selective delivery allows

the payloads' therapeutic window to be modified, which may maintain or enhance drug potency while reducing the number and

severity of adverse events. This platform takes advantage of a metabolic pathway utilized by all tumor cell types in all cell cycle

stages. Compared with other targeted delivery platforms, the PDC platform's mechanism of entry does not rely upon specific

cell surface epitopes or antigens. In addition, PDCs can be conjugated to molecules in numerous ways, thereby increasing the types

of molecules selectively delivered. Cellectar believes the PDC platform holds potential for the discovery and development of the

next generation of cancer-targeting agents.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is focused on the discovery, development

and commercialization of drugs for the treatment of cancer. The company plans to develop proprietary drugs independently and through

research and development (R&D) collaborations. The core drug development strategy is to leverage our PDC platform to develop

therapeutics that specifically target treatment to cancer cells. Through R&D collaborations, the company's strategy is

to generate near-term capital, supplement internal resources, gain access to novel molecules or payloads, accelerate product candidate

development and broaden our proprietary and partnered product pipelines.

The company's lead PDC therapeutic, CLR 131, is in a Phase 1

clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a Phase 2 clinical study in R/R MM and a

range of B-cell malignancies. In 2018 the company plans to initiate a Phase 1 study with CLR 131 in pediatric solid tumors and

lymphoma, and a second Phase 1 study in combination with external beam radiation for head and neck cancer. The company's

product pipeline also includes two preclinical PDC chemotherapeutic programs (CLR 1700 and 1900) and partnered assets include PDCs

from multiple R&D collaborations.

For more information please visit www.cellectar.com.

Forward-Looking Statement Disclaimer

This news release contains forward-looking statements. You can

identify these statements by our use of words such as "may," "expect," "believe," "anticipate,"

"intend," "could," "estimate," "continue," "plans," or their negatives or cognates.

These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause

actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs

and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause

such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties

related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful

preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our

pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical

companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business

is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended

December 31, 2017. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to

update any such forward-looking statements.

LHA Investor Relations